FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978164044> ?p ?o ?g. }

• W1978164044 endingPage "567" @default.
• W1978164044 startingPage "556" @default.
• W1978164044 abstract "Preferentially expressed antigen in melanoma (PRAME) and prostate-specific membrane antigen (PSMA) are tumor-associated antigens implicated in cellular differentiation, genetic stability, and angiogenesis. MKC1106-PP is an immunotherapeutic regimen cotargeting PRAME and PSMA, comprised of a recombinant plasmid (pPRA-PSM encoding fragments derived from both antigens) and 2 peptides (E-PRA and E-PSM derived from PRAME and PSMA, respectively). This multicenter study evaluated MKC1106-PP with a fixed plasmid dose and 2 different peptide doses, administered by intralymph node injection in a prime-boost sequence in human leukocyte antigen-A*0201 and tumor-antigen-positive patients with progressing metastatic solid tumors who had failed standard therapy. Immune monitoring was done by tetramer and enzymatic-linked immune spot analysis. The treatment was well tolerated, with no significant differences in safety, immune response, and clinical outcome relative to peptide doses. Fifteen of 24 evaluable patients showed an immune response, as defined by the expansion of PRAME-specific or PSMA-specific T cells in the blood. There were no partial or complete responses by the Response Evaluation Criteria in Solid Tumors. Seven patients showed stable disease (SD) for 6 months or longer, or prostate specific antigen decline: 4 of 10 with prostate carcinoma, 2 of 2 with renal clear cell carcinoma, and 1 of 10 with metastatic melanoma. In addition, there was an association between the induction and persistence of antigen-specific T cells in blood above baseline levels and disease control, defined as SD for 6 months or longer. These results support further development of MKC1106-PP in specific clinical indications." @default.
• W1978164044 created "2016-06-24" @default.
• W1978164044 creator A5043859862 @default.
• W1978164044 creator A5045399937 @default.
• W1978164044 creator A5047177507 @default.
• W1978164044 creator A5052743765 @default.
• W1978164044 creator A5058943490 @default.
• W1978164044 creator A5059219836 @default.
• W1978164044 creator A5061373605 @default.
• W1978164044 creator A5064185471 @default.
• W1978164044 creator A5072916091 @default.
• W1978164044 creator A5076039798 @default.
• W1978164044 creator A5087802799 @default.
• W1978164044 creator A5089516753 @default.
• W1978164044 date "2011-09-01" @default.
• W1978164044 modified "2023-10-01" @default.
• W1978164044 title "A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors" @default.
• W1978164044 cites W1557495413 @default.
• W1978164044 cites W184777990 @default.
• W1978164044 cites W1873584279 @default.
• W1978164044 cites W1979162850 @default.
• W1978164044 cites W1991891289 @default.
• W1978164044 cites W1991932325 @default.
• W1978164044 cites W1999056177 @default.
• W1978164044 cites W2000966157 @default.
• W1978164044 cites W2003624089 @default.
• W1978164044 cites W2006278799 @default.
• W1978164044 cites W2012810764 @default.
• W1978164044 cites W2013931269 @default.
• W1978164044 cites W2020324589 @default.
• W1978164044 cites W2020933651 @default.
• W1978164044 cites W2029226756 @default.
• W1978164044 cites W2043357427 @default.
• W1978164044 cites W2046800806 @default.
• W1978164044 cites W2070033188 @default.
• W1978164044 cites W2071651938 @default.
• W1978164044 cites W2076060212 @default.
• W1978164044 cites W2089313396 @default.
• W1978164044 cites W2106719462 @default.
• W1978164044 cites W2117384870 @default.
• W1978164044 cites W2117884326 @default.
• W1978164044 cites W2119036007 @default.
• W1978164044 cites W2125685908 @default.
• W1978164044 cites W2126301505 @default.
• W1978164044 cites W2129140009 @default.
• W1978164044 cites W2133267052 @default.
• W1978164044 cites W2135533572 @default.
• W1978164044 cites W2136826429 @default.
• W1978164044 cites W2137723371 @default.
• W1978164044 cites W2148510816 @default.
• W1978164044 cites W2151309693 @default.
• W1978164044 cites W2151883962 @default.
• W1978164044 cites W2165085849 @default.
• W1978164044 cites W2165242935 @default.
• W1978164044 cites W2170037127 @default.
• W1978164044 cites W2170337253 @default.
• W1978164044 cites W2244799239 @default.
• W1978164044 doi "https://doi.org/10.1097/cji.0b013e3182280db1" @default.
• W1978164044 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3709852" @default.
• W1978164044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21760528" @default.
• W1978164044 hasPublicationYear "2011" @default.
• W1978164044 type Work @default.
• W1978164044 sameAs 1978164044 @default.
• W1978164044 citedByCount "72" @default.
• W1978164044 countsByYear W19781640442012 @default.
• W1978164044 countsByYear W19781640442013 @default.
• W1978164044 countsByYear W19781640442014 @default.
• W1978164044 countsByYear W19781640442015 @default.
• W1978164044 countsByYear W19781640442016 @default.
• W1978164044 countsByYear W19781640442017 @default.
• W1978164044 countsByYear W19781640442018 @default.
• W1978164044 countsByYear W19781640442019 @default.
• W1978164044 countsByYear W19781640442020 @default.
• W1978164044 countsByYear W19781640442021 @default.
• W1978164044 countsByYear W19781640442022 @default.
• W1978164044 countsByYear W19781640442023 @default.
• W1978164044 crossrefType "journal-article" @default.
• W1978164044 hasAuthorship W1978164044A5043859862 @default.
• W1978164044 hasAuthorship W1978164044A5045399937 @default.
• W1978164044 hasAuthorship W1978164044A5047177507 @default.
• W1978164044 hasAuthorship W1978164044A5052743765 @default.
• W1978164044 hasAuthorship W1978164044A5058943490 @default.
• W1978164044 hasAuthorship W1978164044A5059219836 @default.
• W1978164044 hasAuthorship W1978164044A5061373605 @default.
• W1978164044 hasAuthorship W1978164044A5064185471 @default.
• W1978164044 hasAuthorship W1978164044A5072916091 @default.
• W1978164044 hasAuthorship W1978164044A5076039798 @default.
• W1978164044 hasAuthorship W1978164044A5087802799 @default.
• W1978164044 hasAuthorship W1978164044A5089516753 @default.
• W1978164044 hasBestOaLocation W19781640442 @default.
• W1978164044 hasConcept C121608353 @default.
• W1978164044 hasConcept C126322002 @default.
• W1978164044 hasConcept C143998085 @default.
• W1978164044 hasConcept C147483822 @default.
• W1978164044 hasConcept C203014093 @default.
• W1978164044 hasConcept C2777658100 @default.
• W1978164044 hasConcept C2777701055 @default.
• W1978164044 hasConcept C2780192828 @default.

• next